Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer
|ClinicalTrials.gov Identifier: NCT01482728|
Recruitment Status : Completed
First Posted : November 30, 2011
Last Update Posted : May 13, 2016
University of Virginia
Information provided by (Responsible Party):
Linda R Duska, University of Virginia
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Completed|
|Actual Primary Completion Date :||May 2015|
|Actual Study Completion Date :||December 2015|
Shah YM, Rowan BG. The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity. Mol Endocrinol. 2005 Mar;19(3):732-48. Epub 2004 Nov 4.
Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem. 1999 Mar 19;274(12):8335-43.
Desouki MM, Rowan BG. SRC kinase and mitogen-activated protein kinases in the progression from normal to malignant endometrium. Clin Cancer Res. 2004 Jan 15;10(2):546-55.